Therefore, we investigated the expression of TRPA1 on peripheral blood leukocytes and the circulating levels of 4-HNE and H2O2 in RA patients treated or not with either the DMARD leflunomide (LFN) or the anti-TNFα adalimumab (ADA). Here, TRPA1 is linked to rheumatoid arthritis.